CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Rilotumumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01039207
NCT01039207Phase 2Completed
CompareCT.gov

A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Gynecologic Oncology Group·interventional·Posted Dec 24, 2009·Updated Sep 7, 2017

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Rilotumumab for Recurrent Fallopian Tube Carcinoma and 2 related conditions. Completed, enrolled 31 participants across 28 sites.

Detailed Summary

This phase II trial studies how well rilotumumab works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has failed to respond to other therapies (persistent) or has returned after a period of improvement (recurrent). Rilotumumab is a type of drug called a monoclonal antibody, and may interfere with the ability of tumor cells to grow and spread by targeting certain cells and blocking them from working.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 24, 2009
Enrollment StartOct 1, 2010
Primary CompletionJul 1, 2012
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.5 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Rilotumumabbiological

Given IV